BioXcel Therapeutics, Inc.: share-based compensation expense
Share-based compensation expense for BioXcel Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All BioXcel Therapeutics, Inc. financial histories
What this measure means
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
Exact concept: us-gaap:ShareBasedCompensation. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2017-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 2,767,000 | USD | 2026-03-27 | 10-K · 0001104659-26-036214 |
| 2024-01-01 | 2024-12-31 | 6,156,000 | USD | 2026-03-27 | 10-K · 0001104659-26-036214 |
| 2023-01-01 | 2023-12-31 | 18,614,000 | USD | 2025-03-28 | 10-K · 0001558370-25-003985 |
| 2022-01-01 | 2022-12-31 | 17,337,000 | USD | 2024-03-22 | 10-K · 0001558370-24-003784 |
| 2021-01-01 | 2021-12-31 | 19,455,000 | USD | 2023-03-16 | 10-K · 0001558370-23-003940 |
| 2020-01-01 | 2020-12-31 | 14,611,000 | USD | 2022-03-11 | 10-K · 0001558370-22-003335 |
| 2019-01-01 | 2019-12-31 | 3,142,000 | USD | 2021-03-12 | 10-K · 0001558370-21-002916 |
| 2018-01-01 | 2018-12-31 | 3,082,000 | USD | 2020-03-09 | 10-K · 0001558370-20-002196 |
| 2017-01-01 | 2017-12-31 | 1,606,000 | USD | 2019-03-12 | 10-K · 0001558370-19-001798 |
Related financial histories
- BioXcel Therapeutics, Inc.: total assets
- BioXcel Therapeutics, Inc.: total liabilities
- BioXcel Therapeutics, Inc.: stockholders equity
- BioXcel Therapeutics, Inc.: cash and cash equivalents
- BioXcel Therapeutics, Inc.: net income or loss
- BioXcel Therapeutics, Inc.: operating cash flow
- BioXcel Therapeutics, Inc.: capital expenditure payments
- BioXcel Therapeutics, Inc.: contract revenue excluding tax
- BioXcel Therapeutics, Inc.: financing cash flow
- BioXcel Therapeutics, Inc.: investing cash flow
- BioXcel Therapeutics, Inc.: retained earnings or deficit
- BioXcel Therapeutics, Inc.: basic weighted-average shares
- BioXcel Therapeutics, Inc.: diluted weighted-average shares
- BioXcel Therapeutics, Inc.: basic earnings per share
- BioXcel Therapeutics, Inc.: diluted earnings per share
- BioXcel Therapeutics, Inc.: net property, plant and equipment
- BioXcel Therapeutics, Inc.: operating income or loss
- BioXcel Therapeutics, Inc.: current assets
- BioXcel Therapeutics, Inc.: interest expense
- BioXcel Therapeutics, Inc.: current liabilities
- BioXcel Therapeutics, Inc.: current accounts payable
- BioXcel Therapeutics, Inc.: operating expenses
- BioXcel Therapeutics, Inc.: net inventory
- BioXcel Therapeutics, Inc.: selling, general and administrative expense
- BioXcel Therapeutics, Inc.: research and development expense
Inspect the source
- Entity
- BioXcel Therapeutics, Inc. / CIK 0001720893
- Captured
- 2026-09-21T17:27:16.004Z
- SEC response SHA-256
3749c1daf0783c3f7926b0c0056af00e3ffcb13aa57dfe693033bf2d42927115
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001720893.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))